Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

Journal of Human Hypertension

Volumn 12, Issue 12, 1998, Pages 861-866

  Benz, J R ^a   Black, H R ^b   Graff, A ^c   Reed, A ^d   Fitzsimmons, S ^e   Shi, Y ^e  

^a Clinical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Smith and Reed Clinic   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin II antagonist; Angiotensin receptor blocker (ARB); AT1 blocker; Essential hypertension; Hydrochlorothiazide; Valsartan

Indexed keywords

ANGIOTENSIN II ANTAGONIST; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SITTING; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VERTIGO;

EID: 0032436072     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000718     Document Type: Article

References (17)

1. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127: 1388-1401.
2. Criscione EL et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1 receptor subtype. Br J Pharmacol 1993; 110: 761-771.
3. Oparil S et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810.
4. Corea L et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther 1996; 60: 341-346.
5. Holwerda NJ et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-1151.
6. Benz J et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-107.
7. Hegner G et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with hydrochlorothiazide. Eur J Clin Pharmacol 1997; 52: 173-177.
8. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNCV). Arch Intern Med 1993; 153: 154-183.
9. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed dose combination therapy. Arch Intern Med 1996; 156: 1969-1978.
10. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979; 25: 33-39.
11. Frishman WH, Goldberger J, Sherman D. Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension. J Clin Hypertens 1987; 3: 520-527.
12. MacKay JH et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-285.
13. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150: 1175-1183.
14. Gavros HP, Salerno CM. The angiotensin II type I receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18: 1058-1067.
15. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ 1993; 307: 1541-1546.
16. McHugh RB, Le CT. Confidence estimation and size of a clinical trial. Controlled Clin Trials 1984; 5: 157-163.
17. Soffer BA et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.